VolitionRx - Executive interview
Volition is a multinational life sciences company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers...
741 Views
VolitionRx - Platform upgrades and busy 2019
VolitionRx's latest Q318 results announcement provided an update on the progress across its established R&D projects and added more detail to...
33 Views
VolitionRx - Shifts in US CRC screening; major catalysts in H2
VolitionRx has broad R&D programme and expects to announce major milestones in the coming months, culminating with CE marking and launch of...
39 Views
VolitionRx - Results from asymptomatic CRC trial reported
VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study...
65 Views
VolitionRx - Big EU trials on deck
In September 2017, VolitionRx announced its European development plan for the Nu.Q™ colorectal cancer (CRC) frontline screening test. It will run...
48 Views